Carvedilol versus Propranolol in Patients with Hepatocellular Carcinoma: A Nationwide Cohort Study [0.03%]
卡维地洛与普萘洛尔治疗肝细胞癌患者的疗效对比：基于全国队列的回顾性研究
Byeong Geun Song,Myeongcheol Lee,Juhee Cho et al.
Byeong Geun Song et al.
Introduction: Beta-blockers reduce portal hypertension; however, evidence comparing carvedilol and propranolol in patients with hepatocellular carcinoma (HCC) is lacking. We aimed to compare the clinical outcomes of carve...
The Regeneration Paradox in Liver Cancer: How Chronic Injury Transforms Healing into Carcinogenesis [0.03%]
肝癌中的再生悖论：慢性损伤如何将修复转化为致癌机制
Chun-Nan Yeh,Miin-Fu Chen
Chun-Nan Yeh
Background: The liver presents a fundamental paradox: it possesses unparalleled regenerative capacity yet demonstrates exquisite cancer susceptibility under chronic injury, with 85-90% of hepatocellular carcinoma (HCC) ar...
Review
Liver cancer. 2026 Jun 25. DOI:10.1159/000550897 2026
Reply to "Methodological Concerns in 'Prognostic Usefulness of Clinical Complete Response after PD-1 Inhibitor-Based Combination Therapy for Unresectable Hepatocellular Carcinoma'" [0.03%]
“PD-1抑制剂为基础的联合治疗用于不可切除肝细胞癌后的临床完全缓解的预后价值”的方法学问题的回答
Da-Long Yang,Jian-Li Huang,Hong-Gui Qin et al.
Da-Long Yang et al.
Acquired Genetic Variants, Not Tumor Mutation Burden, Drive Resistance to Immunotherapy in Hepatocellular Carcinoma [0.03%]
获得的基因变异，而不是肿瘤突变负荷，驱动肝细胞癌免疫治疗耐药性的发展
Jinho Lee,Hye Won Lee,Mi Ri Park et al.
Jinho Lee et al.
Introduction: While immunotherapy has emerged as a promising treatment option, no reliable predictive biomarker has been established for immunotherapy in hepatocellular carcinoma (HCC). In this study, we used genetic anal...
Real-World Evidence from a Nationwide Prospective Study of the Efficacy/Safety of Systemic Therapy for Unresectable Hepatocellular Carcinoma: First 1,000 Patients of the PRISM Study [0.03%]
日本肝癌系统治疗全国前瞻性实效/安全性调查研究(PRISM研究)第一千例结果
Masafumi Ikeda,Shinji Itoh,Daisuke Onozuka et al.
Masafumi Ikeda et al.
Background: The PRISM study is a nationwide, multicenter, prospective observational study in Japan evaluating the real-world efficacy and safety of systemic therapies for unresectable hepatocellular carcinoma (HCC). HCC p...
Masatoshi Kudo
Masatoshi Kudo
Reply to the Comment on the Article "Prognostic Usefulness of Clinical Complete Response after PD-1 Inhibitor Based Combination Therapy for Unresectable Hepatocellular Carcinoma" [0.03%]
对评论的回复：“PD-1抑制剂联合治疗不可切除肝细胞癌后的临床完全缓解的预后价值”
Zhi-Hao Huang,Jian-Li Huang,Lei-Po Lin et al.
Zhi-Hao Huang et al.
Dissecting the Transcriptomic Profile of CD163+ Macrophages in Hepatocellular Carcinoma with VETC+ Angiogenesis Provides Potential Targets of Treatment [0.03%]
通过VETC+血管生成对肝细胞癌中CD163+巨噬细胞转录组谱系的剖析为治疗提供了潜在靶标
Camilla De Carlo,Anna Rita Putignano,Reha Akpinar et al.
Camilla De Carlo et al.
Introduction: Hepatocellular carcinoma (HCC) is characterized by a highly vascularized tumor microenvironment (TME), with VETC being a distinctive, frequent, and prognostically unfavorable type of this vascular TME. VETC+...
Definition of Conversion Therapy and Neoadjuvant Therapy for Hepatocellular Carcinoma: A Consensus Guideline from the Japan Liver Cancer Association [0.03%]
日本肝癌协会肝细胞癌转化治疗和新辅助治疗定义的共识指南
Akihiko Ichida,Ryosuke Tateishi,Etsuro Hatano et al.
Akihiko Ichida et al.
With the advent of novel systemic therapies that provide high response rates, such as lenvatinib, atezolizumab-bevacizumab, durvalumab-tremelimumab, and nivolumab-ipilimumab, treatment strategies for patients with advanced hepatocellular ca...
Lenvatinib Added to Nivolumab and Ipilimumab Improves Tumor Control and Progression-Free Survival in Unresectable Hepatocellular Carcinoma [0.03%]
仑伐替尼联合纳武利尤单抗和伊匹木单抗可改善不可切除肝细胞癌患者的肿瘤控制及无进展生存期
Kuan-Chang Lai,Chien-An Liu,Hao-Jan Lei et al.
Kuan-Chang Lai et al.
Introduction: In CheckMate-9DW, the suboptimal early tumor control of nivolumab-ipilimumab resulted in higher early mortality compared with the sorafenib/lenvatinib arm during the first 12 months. We evaluated whether add...